Prostate Adaptive Radiation Therapy
Recruiting · NCT06547398 · Interventional (participants receive a specific treatment) · Lead sponsor: Royal North Shore Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.
Who can take part
Inclusion criteria
- \- Age \> 18
- Biopsy proven prostate malignancy
- Definitive treatment is radiotherapy to the prostate alone
- ECOG performance status 0-2
- Ability to understand and the willingness to sign an informed consent
Exclusion criteria
- Hip prosthesis
- Patient separation from prostate centre to skin edge \> 24cm, measured on diagnostic scan-
Where it is running
1 location listed.
- Northern Sydney Cancer Centre, Royal North Shore Hospital - St Leonards, New South Wales, Australia